Benadryl vertigo: Management of peripheral vertigo with antihistamines: New options on the horizon
Management of peripheral vertigo with antihistamines: New options on the horizon
1.
Bisdorff A, Von Brevern M, Lempert T, Newman‐Toker DE. Classification of vestibular symptoms: towards an international classification of vestibular disorders. J Vestib Res. 2009;19:1‐13. [PubMed] [Google Scholar]
2.
Murdin L, Schilder AGM. Epidemiology of balance symptoms and disorders in the community: a systematic review. Otol Neurotol. 2015;36(3):387‐392. [PubMed] [Google Scholar]
3.
Neuhauser HK, Lempert T. Vertigo: epidemiologic aspects. Semin Neurol. 2009;29(05):473‐481. [PubMed] [Google Scholar]
4.
Strupp M, Brandt T. Peripheral vestibular disorders. Curr Opin Neurol. 2013;26(1):81‐89. [PubMed] [Google Scholar]
5.
Neuhauser HK. The epidemiology of dizziness and vertigo. Handb Clin Neurol. 2016;137:67‐82. [PubMed] [Google Scholar]
6.
Guth PS, Perin P, Norris CH, Valli P. The vestibular hair cells: post‐transductional signal processing. Prog Neurobiol. 1998;54(2):193‐247.
[PubMed] [Google Scholar]
7.
Soto E, Vega R, Seseña E. Neuropharmacological basis of vestibular system disorder treatment. J Vestib Res. 2013;23(3):119‐137. [PubMed] [Google Scholar]
8.
Bhattacharyya N, Gubbels SP, Schwartz SR, et al. Clinical practice guideline: benign paroxysmal positional vertigo (update). Otolaryngol Head Neck Surg. 2017;156(3_suppl):S1‐S47. [PubMed] [Google Scholar]
9.
Hall CD, Herdman SJ, Whitney SL, et al. Vestibular rehabilitation for peripheral vestibular hypofunction: an evidence‐based clinical practice guideline: from the American Physical Therapy Association neurology section. J Neurol Phys Ther. 2016;40(2):124‐155. [PMC free article] [PubMed] [Google Scholar]
10.
Imai T, Takeda N, Ikezono T, et al. Classification, diagnostic criteria and management of benign paroxysmal positional vertigo. Auris Nasus Larynx. 2017;44(1):1‐6. [PubMed] [Google Scholar]
11.
Hain T. Drug treatment of vertigo. 2017. [cited 2017 Sep 8]; https://www.
dizziness‐and‐balance.com/treatment/drug/drugrx.html. Accessed Sept 2017.
12.
Panula P, Chazot PL, Cowart M, et al. International Union of Basic and Clinical Pharmacology. XCVIII histamine receptors. Pharmacol Rev. 2015;67(3):601‐655. [PMC free article] [PubMed] [Google Scholar]
13.
Panula P, Nuutinen S. The histaminergic network in the brain: basic organization and role in disease. Nat Rev Neurosci. 2013;14(7):472‐487. [PubMed] [Google Scholar]
14.
Nyberg S, Abbott NJ, Shi X, Steyger PS, Dabdoub A. Delivery of therapeutics to the inner ear: the challenge of the blood‐labyrinth barrier. Sci Transl Med. 2019;11(482):eaao0935. [PMC free article] [PubMed] [Google Scholar]
15.
Azuma H, Sawada S, Takeuchi S, Higashiyama K, Kakigi A, Takeda T. Immunohistochemical localization of histamine receptors in rat cochlea. Laryngoscope. 2004;114(12):2249‐2251. [PubMed] [Google Scholar]
16.
Takumida M, Takumida H, Anniko M. Localization of histamine (h2, h3, h4 and h5) receptors in mouse inner ear.
Acta Otolaryngol. 2016;136(6):537‐544. [PubMed] [Google Scholar]
17.
Møller MN, Kirkeby S, Vikeså J, Nielsen FC, Caye‐Thomasen P. Expression of histamine receptors in the human endolymphatic sac: the molecular rationale for betahistine use in Menieres disease. Eur Arch Otorhinolaryngol. 2016;273(7):1705‐1710. [PubMed] [Google Scholar]
18.
Housley GD, Norris CH, Guth PS. Histamine and related substances influence neurotransmission in the semicircular canal. Hear Res. 1988;35(1):87‐97. [PubMed] [Google Scholar]
19.
Peng S‐Y, Zhuang Q‐X, He Y‐C, Zhu J‐N, Wang J‐J. Histamine excites neurons of the inferior vestibular nucleus in rats by activation of h2 and h3 receptors. Neurosci Lett. 2013;541:87‐92. [PubMed] [Google Scholar]
20.
Serafin M, Khateb A, Vibert N, Vidal PP, Mühlethaler M. Medial vestibular nucleus in the Guinea‐pig: histaminergic receptors. I. an in vitro study. Exp Brain Res. 1993;93(2):242‐248. [PubMed] [Google Scholar]
21.
Yabe T, de Waele C, Serafin M, et al.
Medial vestibular nucleus in the Guinea‐pig: histaminergic receptors. II. An in vivo study. Exp Brain Res. 1993;93(2):249‐258. [PubMed] [Google Scholar]
22.
Zhuang Q‐X, Wu Y‐H, Wu G‐Y, Zhu J‐N, Wang J‐J. Histamine excites rat superior vestibular nuclear neurons via postsynaptic h2 and h3 receptors in vitro. Neurosignals. 2013;21(3‐4):174‐183. [PubMed] [Google Scholar]
23.
Horii A, Takeda N, Matsunaga T, et al. Effect of unilateral vestibular stimulation on histamine release from the hypothalamus of rats in vivo. J Neurophysiol. 1993;70(5):1822‐1826. [PubMed] [Google Scholar]
24.
Huang L‐G, Wang E‐T, Chen W, Gong W. Role of histamine h2 receptors in vestibular nucleus in motion sickness. Journal of Otology. 2011;6:20‐25. [Google Scholar]
25.
Tu L, Lu Z, Dieser K, et al. Brain activation by h2 antihistamines challenges conventional view of their mechanism of action in motion sickness: a behavioral, c‐Fos and physiological study in Suncus murinus (house musk shrew).
Front Physiol. 2017;8:412. [PMC free article] [PubMed] [Google Scholar]
26.
Dyhrfjeld‐Johnsen J, Gaboyard‐Niay S, Broussy A, Saleur A, Brugeaud A, Chabbert C. Ondansetron reduces lasting vestibular deficits in a model of severe peripheral excitotoxic injury. J Vestib Res. 2013;23(3):177‐186. [PubMed] [Google Scholar]
27.
Luxon L. Comparison of assessment of caloric nystagmus by observation of duration and by electronystagmographic measurement of slow‐phase velocity. Br J Audiol. 1995;29(2):107‐115. [PubMed] [Google Scholar]
28.
Strupp M, Brandt T. Vestibular neuritis. Semin Neurol. 2009;29(05):509‐519. [PubMed] [Google Scholar]
29.
Witzeman LA. A new treatment for vertigo. Eye Ear Nose Throat Mon. 1949;28:272. [PubMed] [Google Scholar]
30.
Bergquist F, Dutia MB. Central histaminergic modulation of vestibular function ‐ a review. Sheng li Xue Bao. 2006;58(4):293‐304. [PubMed] [Google Scholar]
31.
Amini A, Heidari K, Kariman H, et al. Histamine antagonists for treatment of peripheral vertigo: a meta‐analysis.
J Int Adv Otol. 2015;11(2):138‐142. [PubMed] [Google Scholar]
32.
Kim M‐B, Lee HS, Ban JH. Vestibular suppressants after canalith repositioning in benign paroxysmal positional vertigo. Laryngoscope. 2014;124(10):2400‐2403. [PubMed] [Google Scholar]
33.
Cohen B, DeJong JM. Meclizine and placebo in treating vertigo of vestibular origin. Relative efficacy in a double‐blind study. Arch Neurol. 1972;27(2):129‐135. [PubMed] [Google Scholar]
34.
Shih RD, Walsh B, Eskin B, et al. Diazepam and meclizine are equally effective in the treatment of vertigo: an emergency department randomized double‐blind placebo‐controlled trial. J Emerg Med. 2017;52(1):23‐27. [PubMed] [Google Scholar]
35.
Pianese CP, Hidalgo LOV, González RH, et al. New approaches to the management of peripheral vertigo: efficacy and safety of two calcium antagonists in a 12‐week, multinational, double‐blind study. Otol Neurotol. 2002;23(3):357‐363. [PubMed] [Google Scholar]
36.
Taghdiri F, Togha M, Razeghi Jahromi S, Refaeian F.
Cinnarizine for the prophylaxis of migraine associated vertigo: a retrospective study. Springerplus. 2014;3(1):231. [PMC free article] [PubMed] [Google Scholar]
37.
Cirek Z, Schwarz M, Baumann W, Novotny M. Efficacy and tolerability of a fixed combination of Cinnarizine and Dimenhydrinate versus Betahistine in the treatment of Otogenic vertigo: a double‐blind, randomised clinical study. Clin Drug Investig. 2005;25(6):377‐389. [PubMed] [Google Scholar]
38.
Hahn A, Sejna I, Stefflova B, Schwarz M, Baumann W. A fixed combination of cinnarizine/dimenhydrinate for the treatment of patients with acute vertigo due to vestibular disorders: a randomized, reference‐controlled clinical study. Clin Drug Investig. 2008;28(2):89‐99. [PubMed] [Google Scholar]
39.
Scholtz A‐W, Steindl R, Burchardi N, Bognar‐Steinberg I, Baumann W. Comparison of the therapeutic efficacy of a fixed low‐dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis: a randomized, double‐blind, non‐inferiority study.
Clin Drug Investig. 2012;32(6):387‐399. [PubMed] [Google Scholar]
40.
Scholtz A‐W, Ilgner J, Loader B, Pritschow BW, Weisshaar G. Cinnarizine and dimenhydrinate in the treatment of vertigo in medical practice. Wien Klin Wochenschr. 2016;128(9‐10):341‐347. [PMC free article] [PubMed] [Google Scholar]
41.
Otto V, Fischer B, Schwarz M, Baumann W, Preibisch‐Effenberger R. Treatment of vertebrobasilar insufficiency‐‐associated vertigo with a fixed combination of cinnarizine and dimenhydrinate. Int Tinnitus J. 2008;14:57‐67. [PubMed] [Google Scholar]
42.
Arrang JM, Garbarg M, Quach TT, Dam Trung Tuong M, Yeramian E, Schwartz JC. Actions of betahistine at histamine receptors in the brain. Eur J Pharmacol. 1985;111(1):73‐84. [PubMed] [Google Scholar]
43.
Ramos Alcocer R, Ledezma Rodríguez JG, Navas Romero A, et al. Use of betahistine in the treatment of peripheral vertigo. Acta Otolaryngol. 2015;135(12):1205‐1211. [PubMed] [Google Scholar]
44.
Huppert D, Strupp M, Mückter H, Brandt T.
Which medication do I need to manage dizzy patients?
Acta Otolaryngol. 2011;131(3):228‐241. [PubMed] [Google Scholar]
45.
Lacour M, van de Heyning PH, Novotny M, Tighilet B. Betahistine in the treatment of Ménière’s disease. Neuropsychiatr Dis Treat. 2007;3:429‐440. [PMC free article] [PubMed] [Google Scholar]
46.
Smith WK, Sankar V, Pfleiderer AG. A national survey amongst UK otolaryngologists regarding the treatment of Ménière’s disease. J Laryngol Otol. 2005;119(2):102‐105. [PubMed] [Google Scholar]
47.
Della Pepa C, Guidetti G, Eandi M. Betahistine in the treatment of vertiginous syndromes: a meta‐analysis. Acta Otorhinolaryngol Ital. 2006;26(4):208‐215. [PMC free article] [PubMed] [Google Scholar]
48.
Nauta JJP. Meta‐analysis of clinical studies with betahistine in Ménière’s disease and vestibular vertigo. Eur Arch Otorhinolaryngol. 2014;271(5):887‐897. [PubMed] [Google Scholar]
49.
Murdin L, Hussain K, Schilder AGM. Betahistine for symptoms of vertigo.
Cochrane Database Syst Rev. 2016;2016:CD010696. [PMC free article] [PubMed] [Google Scholar]
50.
Benecke H, Pérez‐Garrigues H, Bin Sidek D, Uloziene I, Sondag E, Theeuwes A. Effects of betahistine on patient‐reported outcomes in routine practice in patients with vestibular vertigo and appraisal of tolerability: experience in the OSVaLD study. Int Tinnitus J. 2010;16(1):14‐24. [PubMed] [Google Scholar]
51.
Adrion C, Fischer CS, Wagner J, Gürkov R, Mansmann U, Strupp M. Efficacy and safety of betahistine treatment in patients with Meniere’s disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ. 2016;352:h6816. [PMC free article] [PubMed] [Google Scholar]
52.
Tighilet B, Léonard J, Watabe I, Bernard‐Demanze L, Lacour M. Betahistine treatment in a cat model of vestibular pathology: pharmacokinetic and Pharmacodynamic approaches. Front Neurol. 2018;9:431. [PMC free article] [PubMed] [Google Scholar]
53.
Tighilet B, Trottier S, Lacour M. Dose‐ and duration‐dependent effects of betahistine dihydrochloride treatment on histamine turnover in the cat. Eur J Pharmacol. 2005;523(1‐3):54‐63. [PubMed] [Google Scholar]
54.
Tighilet B, Trottier S, Mourre C, Chotard C, Lacour M. Betahistine dihydrochloride interaction with the histaminergic system in the cat: neurochemical and molecular mechanisms. Eur J Pharmacol. 2002;446(1‐3):63‐73. [PubMed] [Google Scholar]
55.
Teggi R, Gatti O, Sykopetrites V, Quaglieri S, Benazzo M, Bussi M. Association of cinnarizine and betahistine in prophylactic therapy for Ménière’s disease with and without migraine. Acta Otorhinolaryngol Ital. 2014;34:349‐353. [PMC free article] [PubMed] [Google Scholar]
56.
Lepcha A, Amalanathan S, Augustine AM, Tyagi AK, Balraj A. Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. Eur Arch Otorhinolaryngol. 2014;271(11):2931‐2936. [PubMed] [Google Scholar]
57.
Nagy A, Doros C, Marceanu L, et al.
Treatment of Meniere’s disease with intratympanic dexamethazone plus high dosage of betahistine. Am J Otolaryngol. 2016;37(3):225‐230. [PubMed] [Google Scholar]
58.
Chen XY, Zhong DF, Duan JL, Yan BX. LC‐MS‐MS analysis of 2‐pyridylacetic acid, a major metabolite of betahistine: application to a pharmacokinetic study in healthy volunteers. Xenobiotica. 2003;33(12):1261‐1271. [PubMed] [Google Scholar]
59.
AM‐125 for Vertigo
. Betahistine spray for intranasal use. Fact sheet. Auris medical. October 2018.
https://aurismedical.com/product‐candidates/am‐125. Accessed February 2019.
60.
Dutia MB. Mechanisms of vestibular compensation: recent advances. Curr Opin Otolaryngol Head Neck Surg. 2010;18(5):420‐424. [PubMed] [Google Scholar]
61.
Lacour M, Helmchen C, Vidal P‐P. Vestibular compensation: the neuro‐otologist’s best friend. J Neurol. 2016;263(Suppl 1):S54‐S64. [PMC free article] [PubMed] [Google Scholar]
62.
Bergquist F, Ruthven A, Ludwig M, Dutia MB. Histaminergic and glycinergic modulation of GABA release in the vestibular nuclei of normal and labyrinthectomised rats.
J Physiol (Lond). 2006;577(3):857‐868. [PMC free article] [PubMed] [Google Scholar]
63.
Zhou L, Zhou W, Zhang S, et al. Changes in histamine receptors (h2, h3, and h4) expression in rat medial vestibular nucleus and Flocculus after unilateral Labyrinthectomy: histamine receptors in vestibular compensation. PLoS ONE. 2013;8(6):e66684. [PMC free article] [PubMed] [Google Scholar]
64.
Tighilet B, Mourre C, Lacour M. Plasticity of the histamine h4 receptors after acute vestibular lesion in the adult cat. Front Integr Neurosci. 2014;7:87. [PMC free article] [PubMed] [Google Scholar]
65.
Peppard SB. Effect of drug therapy on compensation from vestibular injury. Laryngoscope. 1986;96(8):878‐898. [PubMed] [Google Scholar]
66.
Tighilet B, Mourre C, Trottier S, Lacour M. Histaminergic ligands improve vestibular compensation in the cat: behavioural, neurochemical and molecular evidence. Eur J Pharmacol. 2007;568(1‐3):149‐163. [PubMed] [Google Scholar]
67.
Redon C, Lopez C, Bernard‐Demanze L, et al.
Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss. J Clin Pharmacol. 2011;51(4):538‐548. [PubMed] [Google Scholar]
68.
Parfenov VA, Golyk VA, Matsnev EI, et al. Effectiveness of betahistine (48 mg/day) in patients with vestibular vertigo during routine practice: the VIRTUOSO study. PLoS ONE. 2017;12(3):e0174114. [PMC free article] [PubMed] [Google Scholar]
69.
Goudakos JK, Markou KD, Psillas G, Vital V, Tsaligopoulos M. Corticosteroids and vestibular exercises in vestibular neuritis. Single‐blind randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2014;140(5):434‐440. [PubMed] [Google Scholar]
70.
Rascol O, Hain TC, Brefel C, Benazet M, Clanet M, Montastruc JL. Antivertigo medications and drug‐induced vertigo. A pharmacological review. Drugs. 1995;50(5):777‐791. [PubMed] [Google Scholar]
71.
Kaski D, Bronstein AM. Making a diagnosis in patients who present with vertigo. BMJ. 2012;345(sep03 1):e5809.
[PubMed] [Google Scholar]
72.
Kiroglu MM, Dagkiran M, Ozdemir S, Surmrlioglu O, Tarkan O. The effects of Betahistine and Dimenhydrinate on caloric test parameters; slow‐phase velocity of nystagmus. J Int Adv Otol. 2014;10(1):68‐71. [Google Scholar]
73.
Walker MF. Treatment of vestibular neuritis. Curr Treat Options Neurol. 2009;11(1):41‐45. [PubMed] [Google Scholar]
74.
Chen Z‐P, Zhang X‐Y, Peng S‐Y, et al. Histamine h2 receptor contributes to vestibular compensation. J Neurosci. 2019;39(3):420‐433. [PMC free article] [PubMed] [Google Scholar]
75.
Timmerman H. Pharmacotherapy of vertigo: any news to be expected?
Acta Otolaryngol Suppl. 1994;513:28‐32. [PubMed] [Google Scholar]
76.
Orzechowski RF, Currie DS, Valancius CA. Comparative anticholinergic activities of 10 histamine h2 receptor antagonists in two functional models. Eur J Pharmacol. 2005;506(3):257‐264. [PubMed] [Google Scholar]
77.
Liu C, Ma X, Jiang X, et al. Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow.
Mol Pharmacol. 2001;59(3):420‐426. [PubMed] [Google Scholar]
78.
Desmadryl G, Gaboyard‐Niay S, Brugeaud A, et al. Histamine h5 receptor antagonists as potent modulators of mammalian vestibular primary neuron excitability. Br J Pharmacol. 2012;167(4):905‐916. [PMC free article] [PubMed] [Google Scholar]
79.
Wersinger E, Gaboyard‐Niay S, Travo C, et al. Symptomatic treatment of vestibular deficits: therapeutic potential of histamine h5 receptors. J Vestib Res. 2013;23(3):153‐159. [PubMed] [Google Scholar]
80.
Zhang X‐Y, Yu L, Zhuang Q‐X, Peng S‐Y, Zhu J‐N, Wang J‐J. Postsynaptic mechanisms underlying the excitatory action of histamine on medial vestibular nucleus neurons in rats. Br J Pharmacol. 2013;170(1):156‐169. [PMC free article] [PubMed] [Google Scholar]
81.
Strakhova MI, Nikkel AL, Manelli AM, et al. Localization of histamine h5 receptors in the central nervous system of human and rat. Brain Res. 2009;1250:41‐48. [PubMed] [Google Scholar]
82.
Feliszek M, Speckmann V, Schacht D, von Lehe M, Stark H, Schlicker E.
A search for functional histamine h5 receptors in the human, Guinea pig and mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(1):11‐17. [PubMed] [Google Scholar]
83.
Petri D, Schlicker E. A search for presynaptic inhibitory histamine receptors in Guinea‐pig tissues: further h4 receptors but no evidence for h5 receptors. Neuropharmacology. 2016;106:129‐134. [PubMed] [Google Scholar]
84.
Pan L, Qi R, Wang J, Zhou W, Liu J, Cai Y. Evidence for a role of orexin/Hypocretin system in vestibular lesion‐induced locomotor abnormalities in rats. Front Neurosci. 2016;10:355. [PMC free article] [PubMed] [Google Scholar]
85.
Alfon J, Sanchez‐Gomez S, Salcedo C, et al. Efficacy of UR‐63325, a new histamine h5 receptor antagonist, in house dust mite‐induced mouse asthma models. Abstract 1302. Am J Respir Crit Care Med. 2011;183:A1302. [Google Scholar]
86.
Dyhrfjeld‐Johnsen J, Wersinger E, Petremann M, et al. Translational predictivity of preclinical studies of the anti‐vertigo drug SENS‐111 for clinical PK/PD relationships.
Abstract PD170. Association for Research in Otolaryngology (ARO), 40th MidWinter Meeting, February 11–15 2017, Baltimore MD, USA. 2017.
87.
Thurmond RL, Venable J, Savall B, et al. Clinical development of histamine h5 receptor antagonists. Handb Exp Pharmacol. 2017;241:301‐320. [PubMed] [Google Scholar]
88.
Murata Y, Song M, Kikuchi H, et al. Phase 2a, randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study of a h5 R‐antagonist (JNJ‐39758979) in Japanese adults with moderate atopic dermatitis. J Dermatol. 2015;42(2):129‐139. [PubMed] [Google Scholar]
89.
Thurmond RL, Greenspan A, Radziszewski W, et al. Toreforant, a histamine h5 receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate therapy: results of 2 phase II studies. J Rheumatol. 2016;43(9):1637‐1642. [PubMed] [Google Scholar]
90.
Salcedo C, Pontes C, Merlos M. Is the h5 receptor a new drug target for allergies and asthma?
Front Biosci (Elite Ed). 2013;5:178‐187.
[PubMed] [Google Scholar]
91.
Venail F, Attali P, Wersinger E, Gomeni R, Poli S, Schmerber S. Safety, tolerability, pharmacokinetics and pharmacokinetic‐pharmacodynamic modelling of the novel h5 receptor inhibitor SENS‐111 using a modified caloric test in healthy subjects. Br J Clin Pharmacol. 2018;84(12):2836‐2848. [PMC free article] [PubMed] [Google Scholar]
92.
Vives R, Cebrecos J, Huguet J, et al. First into man administration of UR‐63325, a new h5R antagonist for the treatment of allergic respiratory diseases. 29th European Academy of Allergy and Clinical Immunology (EAACI) Congress. 2010.
93.
Gutner LB, Gould WJ, Batterman RC. Action of dimenhydrinate (dramamine) and other drugs on vestibular function. AMA Arch Otolaryngol. 1951;53(3):308‐315. [PubMed] [Google Scholar]
94.
Philipszoon AJ. Influence of cinnarizine on the labyrinth and on vertigo. Clin Pharmacol Ther. 1962;3(2):184‐190. [PubMed] [Google Scholar]
95.
Martin N, Oosterveld WJ. The vestibular effects of meclizine hydrochloride‐niacin combination (Antivert).
Acta Otolaryngol. 1970;70(1):6‐9. [PubMed] [Google Scholar]
96.
Carson S, Lee N, Thakurta S. Drug class review: newer antihistamines: final report update 2. Portland (OR): Oregon Health & Science University; 2010.
http://www.ncbi.nlm.nih.gov/books/NBK50558/
97.
Kay G. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol. 2000;105(6):S622‐S627. [PubMed] [Google Scholar]
98.
Amini A, Heidari K, Asadollahi S, et al. Intravenous promethazine versus lorazepam for the treatment of peripheral vertigo in the emergency department: a double blind, randomized clinical trial of efficacy and safety. J Vestib Res. 2014;24(1):39‐47. [PubMed] [Google Scholar]
99.
Marill KA, Walsh MJ, Nelson BK. Intravenous lorazepam versus dimenhydrinate for treatment of vertigo in the emergency department: a randomized clinical trial. Ann Emerg Med. 2000;36(4):310‐319. [PubMed] [Google Scholar]
100.
Ozdemir H, Akinci E, Coskun F. Comparison of the effectiveness of intravenous piracetam and intravenous dimenhydrinate in the treatment of acute peripheral vertigo in the emergency department.
Singapore Med J. 2013;54(11):649‐652. [PubMed] [Google Scholar]
101.
Betts T, Harris D, Gadd E. The effects of two anti‐vertigo drugs (betahistine and prochlorperazine) on driving skills. Br J Clin Pharmacol. 1991;32(4):455‐458. [PMC free article] [PubMed] [Google Scholar]
5 misconceptions about vertigo, dizziness
Speaking of Health
Topics in this Post
- Ear Health
Many adults have experienced dizziness. It could have occurred after standing up too quickly, after a carnival ride, after taking a medication or during a migraine. Many body systems, including your muscles, bones, joints, eyes and the inner ear, must work normally for you to have normal balance. When these systems aren’t functioning well, you can experience balance problems.
About one-third of Americans at some point experience short-term bouts of feeling foggy, unsteady and lightheaded or feeling a spinning sensation.
However, if these sensations recur or affect your life, it is time to talk with your health care provider.
Vertigo vs. dizziness
First, it is important to outline the differences between vertigo and dizziness. While these words are often used interchangeably, they describe different sensations. Dizziness is the feeling of being lightheaded, foggy or unsteady. Vertigo, which is less common than dizziness, is an overall spinning sensation.
Causes of vertigo and dizziness
Several conditions can cause balance problems, and these problems are usually related to a specific sign or symptom. Your health care team can identify the causes of your symptoms.
The most common cause of vertigo is when calcium crystals in your inner ear become dislodged from their normal position. This is called benign paroxysmal positional vertigo. Other causes of vertigo include inflammation of the nerves in your inner ear, migraine, head injury, Meniere’s disease, noncancerous tumor or motion sickness.
Often, the feelings of faintness or lightheadedness are caused by a significant drop in blood pressure, such as if you stand or sit up too quickly. Cardiovascular disease is another common cause.
Joint, muscle or vision problems, or nerve damage to your legs, frequently cause feelings of unsteadiness. Other causes could include medications you take, abnormalities in your inner ear or a neurological condition, such as Parkinson’s disease.
Finally, dizziness can be caused by medications, abnormalities in your inner ear or psychiatric disorders. It also can occur if you are hyperventilating or breathing rapidly.
Common misconceptions
These conditions often are misunderstood. Here are some common misconceptions about vertigo and dizziness:
- Dizziness is always related to ear crystals.
While benign paroxysmal positional vertigo is a common cause of vertigo, it is not associated with symptoms of dizziness. There are many other potential reasons for spells of dizziness.
- Home remedies, like performing the canalith repositioning procedure or flushing your ears, will fix the problem.
Not only can this be harmful, it can cause more problems. Attempting to reposition crystals without instruction from your health care provider can cause the crystals to be moved incorrectly. There have been instances where patients have given themselves a concussion during the process or damaged their eardrums from flushing liquid into their ears. - Dizziness is all in your head.
Unfortunately, some people are told that their symptoms of dizziness or vertigo are not real or a result of mental illness. They are given advice to ignore it, and it will go away. Long-term dizziness and vertigo should not be ignored. Rather, a health care provider should treat these conditions. - Antihistamines, such as meclizine, solve dizziness.
Meclizine is used to prevent and control nausea, vomiting and dizziness caused by motion sickness. It works to block the signals to the brain that cause these symptoms. However, if you have recurring vertigo or dizziness, taking antihistamines is not a good long-term solution. Meclizine can make you feel drowsy, which results in many people falling asleep until the episodes are over. In this situation, the medication is covering the symptoms, but it is not treating the condition. - You just need to deal with this because there are no long-term treatment options.
Recurring vertigo or dizziness can significantly affect your life, such as missing social activities, or disrupting your abilities to drive or work. There is hope. Work with your health care team to identify the correct treatment option for you.
It works to block the signals to the brain that cause these symptoms. However, if you have recurring vertigo or dizziness, taking antihistamines is not a good long-term solution. Meclizine can make you feel drowsy, which results in many people falling asleep until the episodes are over. In this situation, the medication is covering the symptoms, but it is not treating the condition.If you experience sudden vertigo with a decrease in hearing or ringing in your ear, seek emergency medical treatment. These are symptoms of sensorineural hearing loss, an inflammatory disorder probably caused by a virus that affect the nerves in the balance and hearing portions of your inner ear.
Mindy Zenke is a nurse practitioner in Ear, Nose & Throat (ENT/Otorhinolaryngology) in La Crosse, Sparta and Tomah, Wisconsin.
Topics in this Post
- Ear Health
Are you hearing crickets?
Is tinnitus making you miserable?
Treating your child’s hearing loss
Causes, symptoms and treatment of vertigo
Vertigo is a misperception of one’s body in space. This is a fairly common symptom of both neurological and mental, somatic diseases. An average of 15-35% of the population experiences dizziness in their lifetime. Most often these are people after 60 years – 20%, after 70 – 30% and after 80 – 50%.
Regular bouts of dizziness when standing up markedly impair quality of life and can lead to injury due to falling. This is especially dangerous for the elderly. For people of working age, such manifestations in the body often cause a temporary loss of the opportunity to work fully.
Show all
Conventionally, there are 5 main types of dizziness:
- vestibular;
- lipothymic;
- postural;
- cervicogenic;
- psychogenic.
Vestibular vertigo develops due to damage or physiological stimulation of the peripheral vestibular apparatus and central autonomic structures. As a rule, difficulties with orientation in space arise when the head is rotated. All this passes with loss of balance, periodic falls, nausea and other unpleasant manifestations.
Lipothymic vertigo occurs in pre-syncope after excessive use of insulin or insulinoma. A characteristic symptom is “fog” in the head. A similar condition can occur after taking drugs that depress the central nervous system. For example, tranquilizers.
Postural vertigo is due to various walking disorders.
Cervicogenic dizziness is provoked by diseases of the cervical spine. Dizziness in this pathology is the result of pain and limited mobility of the neck.
Psychogenic dizziness is characteristic of people with neuroses and personality disorders. Such attacks are manifested due to feelings of anxiety, panic attacks in various situations.
This type is usually described as a feeling of unsteadiness, the presence of heaviness in the head, a feeling of intoxication. Oscillatory eye movements in this case are absent, but, unlike other varieties, depression may occur afterwards. Treatment of vertigo in women and men includes psychotherapy, vestibular exercises, and antidepressants.
SYMPTOMS OF VERTIGO AND BALANCE
People who experience dizziness more often describe their condition as follows:
- sensation of body movement;
- loss of balance and body tilt to one side;
- feeling of tension, constriction in the head;
- fall for no reason;
- unsteady gait or loss of her confidence.
Symptoms may only get worse with changes in body position or head rotation. Dizziness can come on suddenly and be so severe that you have to sit up or lie down abruptly. It can last a day or even several, although it is often limited to a few minutes.
CAUSES OF Dizziness
There are many causes of dizziness, from diseases of the inner ear to taking certain medications. The most serious are defined as circulatory pathologies in the brain, as well as tumors or brain damage after falls or strong blows.
In many situations, acute vertigo is caused by diseases of the inner ear, benign paroxysmal positional vertigo, Meniere’s disease. Also, often the basis is infectious diseases of the ear.
Less common causes are vertebrobasilar insufficiency, stroke or intracerebral hemorrhage, multiple sclerosis, vestibular migraine, acoustic neuroma, orthostatic hypotension, hypoglycemia (low blood sugar), anemia (low iron), medication.
Inner ear infections
Vestibular neuritis and labyrinthitis are disorders that result from infections. They cause inflammation of the inner ear, or the nerve that connects the inner ear to the brain. After that, the transmission of sensory information from the ear to the brain is disrupted.
The result is hearing loss and balance problems.
Inner ear infections are caused by viruses or bacteria. You can find out about the presence of viruses in the body by the symptoms of an infection of the internal respiratory tract. Its manifestations are noted a few weeks before the onset of dizziness. You can get an infection at any age.
Anatomy of the ear
The inner ear includes a system of tubes and sacs that are filled with fluid. All this is called a labyrinth, the functions of which are hearing and balance. Sound signals from the labyrinth are transmitted to the brain via the vestibulo-cochlear nerve with two branches. One transmits messages from the organ of hearing, and the other from the organs of balance.
The brain processes balance signals sent through the vestibular nerve from the right and left ear. When one party is infected, it sends false signals. This is how information is presented that does not correspond to reality, which leads to dizziness.
Vestibular neuritis (inflammation of the nerve) affects the balance branch. This leads to dizziness, a disturbed sense of oneself in space, a sharp movement of the eyeballs with a fast phase, but there is no transformation with hearing. It may seem to a person that objects are moving around, and when performing coordination exercises, he will usually be mistaken.
Experts also use the term “vestibular neuronitis” (damage to the sensory neurons of the vestibular ganglion). Its symptom is severe, rapidly developing, paroxysmal dizziness. It is often characterized by vomiting, imbalance. Often, the development of symptoms of dizziness is preceded by SARS. Sometimes, a few weeks before the developed clinical picture, patients may notice short bouts of loss of balance.
Labyrinthitis (inflammation of the labyrinth) occurs when an infection affects both branches of the cochleo-vestibular nerve. Then the hearing changes, attacks of dizziness occur. Even with small turns of the head, the symptoms become more pronounced.
Therefore, some people are forced to support their heads with their hands.
Benign paroxysmal positional vertigo (BPPV)
BPPV is one of the most common causes of vertigo, manifested by sudden movements and head waving. The duration of the state is limited to a few seconds or minutes. It occurs when calcium crystals (otoliths) in the inner ear begin to move. Because of this, there is a sensation of rotation of the body.
The causes of BPPV are a history of traumatic brain injury, as well as otitis media. Often, the cause of the disease cannot be identified. Then the diagnosis is confirmed by taking a Dix-Hallpike sample. To do this, the patient quickly lies down from a sitting position and slightly lowers his head, turned 45 degrees. The test is positive if, a couple of seconds later, an attack of dizziness and nystagmus occurs.
Between 20% and 28% of patients with BPPV report symptomatic relief on their own up to a month after the onset of vertigo.
The disease is benign and recurs within the first 12 months in only 15% of cases.
Treatment of BPPV
Treatment includes the Epley maneuver. It allows, with the help of head manipulations, to shift the otolith (crystal) into an insensitive zone – the vestibule of the inner ear.
If the effectiveness of such treatment is low, the patient is additionally prescribed a set of exercises to perform at home. This is Brandt-Deroff gymnastics, according to the method of which you need to practice 2-3 times a day from 1 to 3 weeks. Taking medication in this case usually does not give positive dynamics.
Operations are performed when repositioning techniques fail. Surgical interventions carry the risk of complications in the form of injuries of the facial nerve and hearing loss.
Among the possible operations:
- obstruction of the posterior semicircular canal;
- removal of the vestibular nerve;
- labyrinthectomy;
- selective neurectomy.
Meniere’s disease
A disease characterized by repeated attacks of rotational vertigo. They last several hours and are not without noise in the ears, their congestion or bursting, as well as hearing impairment. It occurs in about 0.2% of the population, usually in people from 40 to 60 years old. The disease is based on the expansion of the endolymphatic system in the inner ear, which leads to the degeneration of the labyrinth receptors.
The disease has the following manifestations:
- dizziness;
- unsteady gait;
- hearing impairment;
- problems with perception of sounds;
- nausea and vomiting;
- ringing in the ears.
Treatment of Meniere’s disease
The treatment of an attack is by taking vestibulosuppressive agents. Prevention of the disease necessarily includes a low-salt diet, avoidance of alcohol and caffeine, the use of betahistine and diuretics.
If the chosen therapy does not lead to positive dynamics, more serious treatment is required. These can be injections of drugs directly into the ear or surgery.
Diagnosis of dizziness
Patients with dizziness undergo Halmagi tests to determine the level of the vestibulo-ocular reflex. Its violation speaks of central and peripheral lesions.
The Halmagi test does not require the use of additional equipment and lengthy preparation. The patient needs to stop looking at the bridge of the nose of a specialist who sits opposite. At the same time, the doctor holds the patient’s head with both hands and turns it from side to side by 15 degrees. With a normal vestibulo-ocular reflex, the eyes remain looking at a given point. If there is a violation, then the gaze turns along with the turn of the head.
Severe dizziness with repeated bouts of vomiting lasts up to 3-4 days, after which the patient improves. Recovery can take up to several months.
In older people, it is usually delayed and often incomplete. If positive dynamics is not observed within a month, then an MRI of the brain and audiometry should be performed to rule out Meniere’s disease.
WHEN SHOULD YOU SEE A DOCTOR?
The alarm should be sounded if dizziness becomes regular or prolonged. Immediate help is needed if you experience severe dizziness and unsteadiness in combination with the following symptoms:
- sudden headache;
- pain in the retrosternal region;
- labored breathing;
- numbness or weakness of limbs;
- fainting;
- rapid or intermittent heartbeat;
- slow or slurred speech;
- problems with coordination;
- ongoing vomiting;
- convulsions;
- sudden hearing loss;
- numbness or asymmetry of the face.
TREATMENT OF VERTIGO
- Treatment of vestibular neuronitis When diagnosed, the patient is hospitalized, but sometimes outpatient treatment is acceptable. In either case, treatment should be aimed at reducing the degree of dizziness, stopping vomiting, and accelerating vestibular compensation. Symptomatic therapy includes the use of vestibular suppressants. When vomiting, injectable forms of drugs are used. The duration of treatment is determined by the complexity of the manifestations of dizziness. However, in most cases they are taken no longer than 3 days. An additional effect is given by a course of corticosteroids and antiviral drugs for middle ear infections. The vestibular apparatus is best stabilized through special gymnastics. At first, it can negatively affect the well-being, but after 2-3 days, therapy should stabilize the condition. You need to repeat gymnastics at least twice a day.
- Tumors of the cerebellopontine angle (acoustic neuroma) Quite a rare cause of vertigo. It manifests itself as a slowly progressive hearing loss and tinnitus. Rotational vertigo is rare, but unsteadiness is often noted. For some time, vestibular disorders may be the only symptom of the disease. After that, hearing disorders begin to be observed. People with a similar problem should have an MRI of the brain with IV contrast. This will help check the patient for the presence of a tumor in the posterior cranial fossa. When a tumor is found, patients need to consult a neurosurgeon for referral for surgery.
- Vertebrobasilar insufficiency and cerebrovascular diseases It is distinguished by the development of a reversible dysfunction of the brain stem, cerebellum and other structures that receive blood through the main and vertebral arteries. Ischemic attacks may occur due to violations of their patency. The reason is atherosclerotic changes, vascular hypoplasia. A little less often, inflammation, extravasal compression of the vertebral artery (with a neck injury) or dissection of the artery become a prerequisite. A key cause of loss of coordination during dizziness is a malfunction in the work of small arteries with high blood pressure, diabetes, or two diseases together. According to statistics, cerebrovascular accidents account for about 6%. The cause of dizziness at normal pressure can be a malfunction in the functioning of both the labyrinth itself due to problems with blood circulation, and a violation in the area of various brain systems. Most patients with vertebrobasilar insufficiency are diagnosed with other neurological symptoms. Separately, dizziness with problems with blood vessels is very rare. In such situations, further diagnosis is required to remove other concomitant factors. You should not associate bouts of dizziness when changing the position of the head with compression of the vertebral arteries. Often, the rapid development of severe dizziness, along with nausea, vomiting and increased pressure, can be perceived as a signal of the development of a cerebrovascular disease. But usually it rises due to severe dizziness and stress. If a person is suspected of having a stroke, they must be urgently hospitalized for examination and immediate treatment. The hospital performs an MRI of the brain, which in a stroke will show a focal lesion of the cerebellum or brain stem.
- Vestibular migraine Vestibular migraine is rarely diagnosed, although it is regarded as a common cause of recurrent non-positional vestibular vertigo. Its manifestations are dizziness of varying severity, combined with migraine and weakness. It can occur both during the migraine attacks themselves, and in the intervals between them. The duration of such attacks – from 3-5 minutes to 2-3 hours, sometimes days. They are not accompanied by noise or ringing in the ears, as well as hearing loss. Such attacks usually recur. The diagnosis of vestibular migraine is made on the basis of the typical clinical picture, as well as in the presence of migraine and after the exclusion of other possible causes of dizziness in women and men. Treatment of the disease, as with ordinary migraine, includes 3 stages: elimination of provoking factors, relief of an attack and preventive measures. Anti-migraine drugs or analgesics, as well as vestibular suppressants, are taken to eliminate vestibular migraine. Prevention is necessary for regular and severe attacks of vestibular migraine. Then specialists prescribe β-blockers and tricyclic antidepressants.
- Treatment of multiple sclerosis The most important thing in the treatment of this diagnosis is the elimination of life-spoiling sensations and related disorders: difficulties with coordination, hearing or vision. Treatment is determined by the cause of dizziness in men and women and the mechanisms of its development. It is important to guarantee the almost complete independence of the patient in everyday life, try to avoid sources of stress and minimize the risks of falls and injuries. Relief of symptoms includes the use of vestibulolytics. The time of their intake should be short and discussed with the doctor, because the inhibition of nerve formations does not allow compensatory changes to develop. The effectiveness of treatment increases with regular gymnastics, as well as exercises to restore the stable functioning of the vestibular apparatus. Therapy is also important to improve coordination, stabilize gait, and develop skills in a person to avoid balance problems in the future. Usually, physiotherapy exercises are used for this, which not only reduces discomfort, but also gives independence when moving.
It manifests itself as a slowly progressive hearing loss and tinnitus. Rotational vertigo is rare, but unsteadiness is often noted. For some time, vestibular disorders may be the only symptom of the disease. After that, hearing disorders begin to be observed. People with a similar problem should have an MRI of the brain with IV contrast. This will help check the patient for the presence of a tumor in the posterior cranial fossa. When a tumor is found, patients need to consult a neurosurgeon for referral for surgery.
A key cause of loss of coordination during dizziness is a malfunction in the work of small arteries with high blood pressure, diabetes, or two diseases together. According to statistics, cerebrovascular accidents account for about 6%. The cause of dizziness at normal pressure can be a malfunction in the functioning of both the labyrinth itself due to problems with blood circulation, and a violation in the area of various brain systems. Most patients with vertebrobasilar insufficiency are diagnosed with other neurological symptoms. Separately, dizziness with problems with blood vessels is very rare. In such situations, further diagnosis is required to remove other concomitant factors. You should not associate bouts of dizziness when changing the position of the head with compression of the vertebral arteries. Often, the rapid development of severe dizziness, along with nausea, vomiting and increased pressure, can be perceived as a signal of the development of a cerebrovascular disease.
But usually it rises due to severe dizziness and stress. If a person is suspected of having a stroke, they must be urgently hospitalized for examination and immediate treatment. The hospital performs an MRI of the brain, which in a stroke will show a focal lesion of the cerebellum or brain stem.
Treatment of the disease, as with ordinary migraine, includes 3 stages: elimination of provoking factors, relief of an attack and preventive measures. Anti-migraine drugs or analgesics, as well as vestibular suppressants, are taken to eliminate vestibular migraine. Prevention is necessary for regular and severe attacks of vestibular migraine. Then specialists prescribe β-blockers and tricyclic antidepressants.
The effectiveness of treatment increases with regular gymnastics, as well as exercises to restore the stable functioning of the vestibular apparatus. Therapy is also important to improve coordination, stabilize gait, and develop skills in a person to avoid balance problems in the future. Usually, physiotherapy exercises are used for this, which not only reduces discomfort, but also gives independence when moving.Demyelinating disorders (multiple sclerosis)
People with demyelinating lesions of the CNS, especially those with multiple sclerosis, may be diagnosed with vertigo. Diagnostic difficulties may occur when dizziness develops at the onset of the disease without other manifestations or with their moderate severity. Dizziness in this case can be of a mixed nature, and also be characterized by a persistent course. To confirm the diagnosis, the patient needs to undergo an MRI of the brain with intravenous contrast.
HADASSAH MEDICAL MOSCOW PERFORMS DIAGNOSIS AND TREATMENT OF VERTIGO
- CT of the temporal bones and MRI of the brain;
- Ultrasound of neck vessels;
- Audiometry;
- Neurologist appointment;
- ENT doctor’s appointment;
- General practitioner appointment;
- Diagnostic tests to verify BPPV and vestibular neuronitis.
Sources
- Diagnosis and treatment of balance disorders in diseases of the nervous system. Clinical guidelines, Moscow, 2017.
- Jahn K, Kressig RW, Bridenbaugh SA, Brandt T, Schniepp R. Dizziness and Unstable Gait in Old Age: Etiology, Diagnosis and Treatment. Dtsch Arztebl Int. 2015 Jun 5;112(23):387-93. doi: 10.3238/arztebl.2015.0387.
- Neurology: A practitioner’s guide / D.R. Shtulman, O.S. Levin. – 6th ed., add. and perab. — M.: MEDpress-inform, 2008. —— 1024 p.
- Brandt T., Dieterich M., Strupp M. Vertigo: per. from English. // M.: Practice, 2009.
- Parfenov V.A., Zamergrad M.V., Melnikov O.A. Dizziness: Diagnosis and Treatment, Common Diagnostic Mistakes: A Study Guide. // M.: MIA, 2009.
- V. Parfenov, N. Bestuzheva. Diagnosis and treatment of dizziness in outpatient practice // Vrach, 2012
- Neurology. National leadership. Brief edition / ed. E. I. Guseva, A. N. Konovalova, A. B. Gekht. — M.: GEOTAR-Media, 2018 — 688 p.
— M.: GEOTAR-Media, 2018 — 688 p.#DavidovNR
Davidov
Natan Rashbilovich
Neurologist, Ph.D.
Work experience: 10 years
Published: 07/09/2023
The information provided on the site is for reference only and cannot serve as a basis for making a diagnosis or prescribing treatment. Internal consultation of the expert is necessary.
Neurologists
All doctors
Davidov
Natan Rashbilovich
Neurologist, Ph.D.
Work experience: 10 years
Reviews: 2
Cost of admission: from 8000 ₽
Make an appointment
Luneva
Irina Evgenievna ENMG specialist
Work experience: 7
Reviews : 1
Admission fee: from 6500 ₽
Make an appointment
Work experience: 6 years
Reviews:
Appointment fee: from 9000 ₽
Make an appointment
Podgurskaya
Maria Gennadievna
Neurologist, functional diagnostician
Work experience: 5 years
Reviews :
Make an appointment
All doctors
Prices for neurology services
Neurology
| Primary appointment (examination, consultation) with a neurologist | 6,500 ₽ | Repeated appointment (examination, consultation) with a neurologist | 5,500 ₽ |
| Preventive appointment (examination, consultation) with a neurologist | 2,500 ₽ |
| Preventive appointment (examination, consultation) with a neurologist in medical examination | 3 500 ₽ |
| Appointment (examination, consultation) with a neurologist, PhD, primary | ||
| Appointment (examination, consultation) with a neurologist, candidate of medical sciences, repeated | 7 500 ₽ neurologist primary | 6 500 ₽ |
| Remote consultation of a neurologist repeated | 5 500 ₽ | |
| Remote consultation of a neurologist, PhD, primary | 9 000 ₽ | |
| 7 500 ₽ |
D. , repeated| Botulinum toxin type A injection, 1 vial (without drug cost) | 8 600 ₽ |
| Injection of botulinum toxin type A, 2 bottles (without the cost of the drug) | 14 300 ₽ |
| Remote consultation of a neurologist, rehabilitologist, head of the neuro-rehabilitation unit of the Multiple Sclerosis Center of the Khaim Medical Center Sheba (Tel Hashomer) Doleva Mark | 82 500 ₽ |
| Remote consultation of a neurologist, a leading specialist in the Department of Pediatric Neurology at the Edmond and Lily Safra Children’s Hospital of the Chaim Sheba Medical Center (Tel Hashomer) Michal Zadok | 60 500 ₽ |
| Remote consultation Neurologist, Professor, Head of the Department of Pediatric Neurology at the Edmond and Lily Safra Children’s Hospital of the Chaim Sheba Medical Center (Tel Hashomer) Bruria Ben-Zeev | 83 500 ₽ |
| Remote consultation of a neurologist, professor, head of the Department of Movement Disorders of the Institute of Neurology at the Sourasky Medical Center (Ichilov, Tel Aviv) Tatyana Gurevich | 90 000 ₽ | Remote consultation of a neurologist, professor , Head of the Institute of Electromyography and Neurophysiology, Department of Neurology, Sourasky Medical Center (Ichilov, Tel Aviv) Vivienne Drori | 112,000 ₽ |
| Remote consultation of neurologist, epileptologist at Chaim Sheba Medical Center (Tel Hashomer) Naum Margolin | 72 500 ₽ |
| Appointment (examination, consultation) with a neurologist at home within 10 km from the Skolkovo Innovation Center | 14,000 ₽ |
| Reception (examination, consultation) of a neurologist with home visits within 20 km from the Skolkovo Innovation Center | 16,000 ₽ |
| Reception (examination, consultation) of a neurologist with a home visit within 30 km from the Skolkovo Innovation Center | 24,500 ₽ |
| Nerve trunk block | 5 100 ₽ |
| Trigger point block, zone 1 | 5 100 ₽ |
| Unilateral paravertebral block, cervical level | 3,700 RUB |
| Unilateral paravertebral block, thoracic level | RUB 3,700 |
| Bilateral paravertebral block, cervical level | |
| Paravertebral block bilateral, thoracic level | 5 100 ₽ |
| Paravertebral bilateral blockade, lumbar level | 5 900 ₽ |
| Paravertebral block, including the cost of drugs ₽ |
| Reflexology session for diseases of the central nervous system (45 minutes) | 7 200 ₽ | |
| Reflexology session for diseases of the peripheral nervous system (45 minutes) | 7 200 ₽ | |
| Reflexology session for diseases of the musculoskeletal system (45 minutes) | 7 200 RUB x spine (60 minutes) | 8000 ₽ |
| therapy for diseases of the joints (60 minutes) | 8 000 ₽ | |
| Vertebral therapy session for diseases of the central nervous system (60 minutes) | 8 000 ₽ | |
| Vertebral therapy session for diseases of the peripheral nervous system (60 minutes) | 8 000 ₽ |
9034 6
| Focused shock wave therapy (up to 2000 shocks) | $100 |
| Focused shock wave therapy (up to 4500 shocks) | $94 |
| Focused shock wave (over 4500 strokes) | 10 100 ₽ |
| Focused shock wave therapy for myofascial pain syndrome, spine (up to 4500 shocks) | 11 500 ₽ |
| Focused shock wave therapy for myofascial pain syndrome, spine (over 4500 shocks) | 12 900 ₽ |
| Focused shock wave therapy in the treatment of diseases of the shoulder joint treatment of diseases of the hip joint | 11 500 ₽ |
| Focused shock wave therapy in the treatment of diseases of the elbow joint (epicondylitis) | 10 100 ₽ |
| Focused shock wave therapy in the treatment of diseases of the knee joint | 10 100 ₽ |
| Focused shock wave therapy for plantar fasciitis | 10 100 ₽ |
| Focused shock wave therapy for bilateral plantar fasciitis | 14,300 RUB |
| Focused shockwave therapy for the treatment of Achilles tendon disease | 10,100 RUB |
| Focused shockwave therapy therapy for delayed healing of bone fractures and stress fractures | 10 100 ₽ |
| Focused shock-wave therapy for loading periosteopathy, aseptic necrosis (up to 3,000 strokes) | 10 100 ₽ |
| Focused shock-wave therapy for postoperative restoration (removal of edema, pain, up to 3000 shots) | 10 100 ₽ |
| Focused shock wave therapy for postoperative recovery (removal of swelling, pain, over 3000 strokes) | 11 500 ₽ |
| Focused shock wave therapy in the treatment of trophic skin lesions (one segment) | 10 100 ₽ |
| Focused shock wave therapy in the treatment of trophic skin lesions (two segments) | 12 900 ₽ |
9000 3
Advantages of the Hadassah Clinic
Our Clinic
Still have questions?
Leave your number and we will contact you
By clicking on the button, you agree to the terms of use and processing of personal data
Licenses
Link between Benadryl and anxiety – Drink-Drink
DrinkDrinkAdmin
Contents
- Can Benadryl cause anxiety?
- Why is this happening?
- How common is this? How to Take Benadryl Safely 012
- Benadryl tablets or capsules
- Liquid Benadryl
- Tips for taking Benadryl safely
- When to call your doctor if you have taken Benadryl and are feeling anxious
- Emergency
- Conclusion
Benadryl is a type of antihistamine available without a prescription. It is most commonly used to relieve allergy symptoms such as:
- runny nose
- sneezing
- itching
The active ingredient in Benadryl is called diphenhydramine. Like any medicine, Benadryl has a number of side effects. Here are some of the most common:
- feeling sleepy or sleepy
- dry mouth or throat
- dizziness
It is also possible that after taking Benadryl some people may feel:
- restless 900 14
- excitable
- anxious
Keep reading to find out why it happens and what to do if it happens.
Can Benadryl cause anxiety?
One of the most common side effects of Benadryl is drowsiness. Because of this, some people use Benadryl as a sleep aid.
However, it is also possible that Benadryl can do the opposite. When a drug has an effect opposite to what is expected, it is called a paradoxical effect.
In some people, Benadryl can actually have a stimulating effect called paradoxical arousal. People who experience this after taking Benadryl may report feeling:
- excitable
- nervous
- anxious
- restless
- excited
- awake
- hyper
Why is this happening?
It is generally not known why some people develop paradoxical arousal and others do not.
One theory from a 2008 case report is related to the type of genetic variation. Three people who reported paradoxical excitability in response to diphenhydramine had extra copies of a particular gene.
This gene encodes instructions for the production of the CYP2D6 enzyme.
CYP2D6 is important for the breakdown (metabolism) of certain types of drugs such as Benadryl. The presence of additional CYP2D6 can significantly speed up the metabolism of Benadryl.
The aforementioned researchers suggested that in these people Benadryl could be rapidly broken down into substances that cause excitability rather than sedation. However, further studies are needed to confirm this.
How common is this?
There is currently no estimate of how common paradoxical arousal is in people taking Benadryl.
If the fast metabolism theory is correct, it could affect a significant number of people in the United States. The 2008 report reviewed above indicates that between 1% and 2% of people in the United States have a genetic variation.
In addition, paradoxical arousal seems to be more common in children. You will actually see this effect on Benadryl product labels.
Benadryl and Central Nervous System Depression
Benadryl may slow down or depress the functions of your central nervous system (CNS).
This is what can lead to some of the common side effects of Benadryl, such as drowsiness or dizziness. This is why some people may use Benadryl to help them fall asleep or feel less restless.
Other side effects of Benadryl
Now that we have discussed how Benadryl can be associated with feelings of excitability or anxiety, you may be wondering if Benadryl has any other similar side effects. Let’s look at it now.
Benadryl addiction
A person can become dependent on Benadryl. According to the National Health Service, this can happen if it is used frequently over a period of time, such as if you use Benadryl every day for 2 weeks or longer.
When someone becomes addicted to a substance, they may also experience withdrawal symptoms after they stop using it. These may include:
- tremor
- insomnia
- anxiety
It is important to always take Benadryl according to the directions on the product label or your doctor.
Because chronic use of Benadryl can lead to addiction, call your doctor if you find yourself taking Benadryl frequently to treat conditions such as allergies or sleep. They may recommend alternative medications that you can try instead.
Benadryl and dementia
It is possible that prolonged use of Benadryl may increase the risk of developing dementia. 2015 study description of a group of 3,434 people.
The study showed that higher cumulative intake of anticholinergic drugs was associated with an increased risk of dementia in this group. Examples of some types of anticholinergics include:
- first generation antihistamines such as Benadryl
- tricyclic antidepressants (TCAs)
- certain medicines used to treat overactive bladder
- medicines used to treat symptoms of Parkinson’s disease
If you are concerned about Benadryl and dementia, be sure to take Benadryl only for a short period of time. You can also ask your doctor about alternative medicines that may help treat your symptoms.
How to safely take Benadryl
Benadryl can be found in several forms, including:
- Tablets
- Capsules
- liquids
You can find Benadryl products available without a prescription at grocery stores and pharmacies.
Benadryl tablets or capsules
According to the National Institutes of Health, Benadryl tablets or capsules contain 25 milligrams of diphenhydramine, the active ingredient. Recommended dosage of Benadryl:
- Ages 12 and over: Total 1 to 2 tablets every 4-6 hours
- Ages 6 to 12: tablets every 4-6 hours
- Up to 6 years: take
- 6 to 12 years: just 1 to 2 teaspoons (5 to 10 milliliters) every 4 to 6 hours
- 4 to 6 years: use only under the direction of your child’s pediatrician
- Under 4 years: take
- Do not take too much in a day. Avoid taking more than 6 doses of Benadryl within 24 hours.
- Use only as needed. Because Benadryl can cause long-term side effects, be sure to only take it for a short amount of time.
- Avoid other sedatives. Because Benadryl often has a sedative effect, avoid taking it with other sedatives, sleeping pills, or alcohol.
- Be careful with activities. Since Benadryl may cause drowsiness, avoid driving or operating heavy machinery after taking it.
- Talk to your doctor if you:
- are taking sedatives or a type of antidepressant called a monoamine oxidase inhibitor (MAOI)
- have lung disease (asthma, chronic bronchitis, or emphysema)
- you have glaucoma, stomach ulcer , cramps or urinary problems due to an enlarged prostate
- pregnant or breastfeeding
- previously had an allergic reaction to Benadryl
- restlessness
- nervousness
- agitation
- taking deep breaths or slowly counting to 10 can help you feel calmer
- avoiding other stimulants, such as caffeine or nicotine
- exercising to help lift your spirits
- try relaxing activities, such as yoga or meditation
- bladder emptying problems (urinary retention)
- confusion or disorientation
- hallucinations
- low blood pressure (hypotension)
- seizures
- coma
9002 3
Liquid Benadryl
There are also liquid forms of Benadryl that can be used for children. When measuring liquid Benadryl, it is important to use the small cup that comes with the medicine. Do not measure with a kitchen spoon.
According to the National Institutes of Health, the recommended dosage for this type of Benadryl is:
Tips for taking Benadryl safely
It is also important to follow the guidelines below to make sure you take Benadryl safely and reduce the risk of side effects:
Avoid taking more than 6 doses of Benadryl within 24 hours.When to call your doctor if you have taken Benadryl and are worried
Generally speaking, you do not need to call a doctor if you have taken Benadryl and feeling:
The feeling of paradoxical excitement usually only lasts for as long as Benadryl is in your system.
It can be 4 to 6 hours.
Instead, you can try:
Talk to your doctor if you want to recommend alternative medicines that are less likely to have these side effects.
Emergency Medical Services
Taking too much Benadryl can lead to an overdose. If you or someone else has taken Benadryl and you have any of the following symptoms, go to the emergency room or call 911. late pupils
One of the most common side effects of Benadryl is drowsiness.